Welcome to our dedicated page for Acrivon Therapeutics SEC filings (Ticker: ACRV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Clinical-stage biotech filings can read like a graduate textbook—especially when Acrivon Therapeutics packs its 10-K with proteomics jargon, trial protocols, and liquidity tables. If you’re searching “Acrivon Therapeutics SEC filings explained simply” or wondering how platinum-resistant ovarian cancer data affects the balance sheet, you’re in the right place. Stock Titan’s AI dissects every page the moment it hits EDGAR, so you spend minutes—not hours—finding what matters.
Need to track “Acrivon Therapeutics insider trading Form 4 transactions” before the next readout? Our dashboard streams Form 4 insider transactions in real time, flags option exercises, and links them to upcoming milestones disclosed in 8-Ks. Curious about cash runway? The quarterly earnings report 10-Q filing is paired with plain-English summaries that spotlight R&D spend, burn rate, and AP3 platform progress. We also map risk-factor changes between annual report 10-K filings, highlight any shelf-registration clues in S-3s, and surface board votes from the latest proxy statement on executive compensation.
Whether you’re parsing an “Acrivon Therapeutics earnings report filing analysis,” monitoring “Acrivon Therapeutics executive stock transactions Form 4,” or decoding an “Acrivon Therapeutics 8-K material events explained,” Stock Titan delivers comprehensive coverage. Our AI-powered summaries translate dense pathway diagrams into actionable insights, while expert commentary points out dilution risk and regulatory catalysts. Set custom alerts to know the second a new study start appears, compare segment performance across periods, and keep a pulse on WEE1/PKMYT1 clinical updates. All ACRV filings, all in one place, always up to date.
Acrivon Therapeutics, Inc. insiders report routine share withholding for taxes. President and CEO Dr. Peter Blume-Jensen reported that on 11/21/2025, 19,904 shares of common stock were disposed of at $2.30 per share, identified as shares withheld by the company to satisfy mandatory tax withholding upon the vesting of restricted stock units. Following this transaction, he beneficially owned 2,046,771 shares directly and 314,706 shares indirectly.
The indirect holdings reflect spousal ownership between co-founders Dr. Blume-Jensen and EVP – Business Operations Dr. Kristina Masson. Each spouse disclaims beneficial ownership of the other's securities except to the extent of their pecuniary interest, which clarifies how their combined economic exposure to Acrivon’s stock is reported.
Acrivon Therapeutics, Inc. (ACRV)
Acrivon Therapeutics, Inc. reported an insider equity transaction involving its Chief Legal Officer. On 11/14/2025, 184 shares of common stock were disposed of at a price of $2.24 per share. The filing explains that these shares were withheld by the company to satisfy mandatory tax withholding upon the vesting of restricted stock units, rather than being sold in an open-market transaction.
After this tax withholding event, the reporting officer beneficially owns 34,555 shares of Acrivon Therapeutics common stock, held directly. The Form 4 is filed by a single reporting person and reflects routine equity compensation administration for the officer role.
Acrivon Therapeutics, Inc. reported an insider equity transaction by its Chief Development Officer. On 11/14/2025, 403 shares of Acrivon Therapeutics common stock were disposed of at a price of $2.24 per share. The filing explains that these shares were withheld by the company to satisfy mandatory tax withholding upon the vesting of restricted stock units, rather than being an open-market sale. Following this withholding event, the officer beneficially owned 15,283 shares of Acrivon Therapeutics common stock, held directly.
Acrivon Therapeutics, Inc. reported a routine insider equity transaction by its Chief Operating Officer. On 11/14/2025, 613 shares of Acrivon common stock were withheld at a price of $2.24 per share to cover mandatory tax withholding when restricted stock units vested. After this tax-related withholding, the officer beneficially owns 65,308 shares of Acrivon common stock in direct ownership. The filing is administrative in nature and reflects standard equity compensation and tax settlement practices for a senior executive.
Acrivon Therapeutics, Inc. insiders reported routine tax‑related share transactions. On 11/14/2025, President and CEO Dr. Peter Blume-Jensen had 59,765 shares of common stock withheld by the company at $2.24 per share to cover mandatory tax withholding upon vesting of restricted stock units, leaving him with 2,066,675 shares held directly. On the same date, 490 shares were similarly withheld at $2.24 per share from holdings reported as indirect, leaving 314,706 shares held indirectly. The filing notes that Dr. Blume-Jensen and co-founder and EVP – Business Operations Dr. Kristina Masson are spouses and each disclaims beneficial ownership of the other’s securities except to the extent of their pecuniary interest.
Acrivon Therapeutics (ACRV) reported Q3 2025 results, highlighting continued investment in its precision oncology programs. The company posted a net loss of
For the nine months ended September 30, net loss was
Pipeline progress continued. The registrational‑intent Phase 2 trial of ACR‑368 in endometrial cancer previously reported a 35% confirmed ORR and 80% tumor shrinkage in OncoSignature‑positive patients. The ACR‑368 OncoSignature test has FDA Breakthrough Device designation, and ACR‑368 holds Fast Track status. ACR‑2316, a WEE1/PKMYT1 inhibitor, is in Phase 1 with initial signs of activity, including a confirmed partial response at dose level 3. As of
Acrivon Therapeutics, Inc. furnished an 8‑K announcing it issued a press release covering financial results for the quarter ended September 30, 2025, and business updates. The press release is included as Exhibit 99.1 dated November 13, 2025.
The company states that the information in Item 2.02 and Exhibit 99.1 is furnished and not deemed “filed” under Section 18 of the Exchange Act, nor incorporated by reference into other SEC filings.
Acrivon Therapeutics (ACRV) insider activity: The Chief Legal Officer reported a routine tax-withholding event tied to restricted stock unit vesting. On 10/17/2025, a Form 4 shows transaction code F, where 558 shares of common stock were withheld by the issuer at $1.81 to satisfy mandatory taxes. After this administrative transaction, the officer directly beneficially owns 34,739 shares.
Mirza Mansoor Raza, the company Chief Medical Officer, reported acquiring 225,000 stock options in Acrivon Therapeutics, Inc. (ACRV) on 10/01/2025. The options carry an exercise price of $1.81 and are reported as acquired (Transaction Code A), leaving the reporting person with 225,000 derivative securities beneficially owned following the transaction. The filing states vesting terms: 25% vests on November 1, 2026, with the remainder vesting in 36 substantially equal monthly installments thereafter, subject to continued service. The Form 4 was signed by an attorney-in-fact on 10/03/2025.
FAQ
What is the current stock price of Acrivon Therapeutics (ACRV)?
What is the market cap of Acrivon Therapeutics (ACRV)?
